tsc-101
·Code: TSC-101
tsc-101: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| TScan Therapeutics, Inc. (TCRX) | Phase 1 |
FDA Decisions
FDA_MeetingFDA agreed to a pivotal study design that mirrors the current Phase 1 ALLOHA trial, including a biologically assigned internal control arm.(TCRX)
Frequently asked questions
Who is developing tsc-101?
tsc-101 is being developed by TScan Therapeutics, Inc..
What is tsc-101's latest FDA decision?
The most recent tracked FDA decision for tsc-101 is FDA_Meeting for FDA agreed to a pivotal study design that mirrors the current Phase 1 ALLOHA trial, including a biologically assigned internal control arm., dated October 1, 2025.
Get deeper analysis on tsc-101
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis